Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06079671 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06079671 · ClinicalTrials.gov record · last posted 2026-08-25

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Name: Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) — clinical trial record (NCT06079671)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: eVOLVECervical

StatusRecruiting

PhasePhase 3

SponsorAstraZeneca

Started2023-09-22

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Protocol amendment history 1 change detected by DataLookout

2026-05-01

Trial sites expanded: 201 → 204 locations

Trial Details

NCT Number	NCT06079671
Lead Sponsor	AstraZeneca Collaborators: Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Conditions	Locally Advanced Cervical Cancer
Enrollment	800 participants
Start Date	2023-09-22
Primary Completion	2027-11-26 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-25